Glenmark Pharmaceuticals has slashed the price of breast cancer drug Trastuzumab by bringing its brand Trumab at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier. Trastuzumab is used in the treatment of a particular type of breast cancer HER2-positive and the company markets its version in India under the brand name 'Trumab'.
This price reduction will bring the per mg cost of Trumab to around Rs 35, making it the most affordable treatment option for HER2-positive breast cancer in the country.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.90 |
Dr. Reddys Lab | 5788.90 |
Cipla | 1449.20 |
Zydus Lifesciences | 1034.85 |
Lupin | 1585.65 |
View more.. |